Geron halts Phase 3 IMpactMF trial for imetelstat after DMC doubts survival benefit
Geron announced the immediate discontinuation of its Phase 3 IMpactMF study of imetelstat in relapsed/refractory myelofibrosis following a recommendation from an independent Data Monitoring Committee that the trial was unlikely to meet its primary overall‑survival endpoint. The study had enrolled 327 patients and no new safety signals were observed. Geron said it will analyze the data and later share the findings, while continuing to focus on its approved RYTELO product for lower‑risk myelodysplastic syndromes.
Why it matters
The halt removes a key growth catalyst for Geron, causing the stock to drop sharply in pre‑market trading. Investors will now look to upcoming earnings and RYTELO sales for the company's near‑term outlook.
Key facts
- 1The independent Data Monitoring Committee advised Geron that the trial was unlikely to meet its primary overall‑survival endpoint. stocktitan.net
- 2Geron will conduct a detailed analysis of the trial data and share the findings with the scientific community at a later date. stocktitan.net
- 3The IMpactMF trial enrolled 327 patients with intermediate‑2 or high‑risk myelofibrosis who were relapsed or refractory to a JAK inhibitor. stocktitan.net
- 4No new safety signals were identified in the trial. stocktitan.net
- 5Geron’s shares fell 10.4% to $1.03 in pre‑open trading after the announcement. investing.com
Open questions
- Two sources report different pre‑market price declines: 12% (source 4) and 10.4% to $1.03 (source 5).
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.